Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Conditions
Brief summary
PACT is a non-randomized multicentre phase I/II study to evaluate the feasibility and safety of the prophylactic administration of donor derived TCM. Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) who are planned to undergo a HLA -matched (9/10 or 10/10) allogeneic hematopoietic stem cell transplantation and who are either 50+ years old or have a high comorbidity score are included according to criteria as described below. TCM will be applied in escalating doses to a maximum of 30 patients who have received T cell depleted Human leukocyte antigen (HLA)-matched alloHSCT grafts and qualify for TCM transfer.
Detailed description
One of the major challenges in the field of allo-SCT is to find a balance between the harmful induction of graft-versus-host disease (GVHD) and the beneficial graft-versus-leukemia (GVL) response, both mediated by donor T cells recognizing antigens expressed on cells of the recipient. Complete removal of T cells from the graft results in abrogation of severe GVHD, but is also frequently associated with removal of the immunity against infectious agents and the anti-tumor efficacy (GVT effect), which is reflected by an increased incidence of infectious complications and (early) disease relapses after T cell depleted allo-SCT. The investigators hypothesize that the prophylactic adoptive transfer of donor-derived central memory T cells is a safe and tolerable method to improve overall survival after HSCT. TCM are administered in escalating doses at day 30, day 60 and day 90 posttransplant to prevent infectious complications and early relapse or disease progression.
Interventions
BIOLOGICALTCM allogeneic humane central memory T cells, cryopreserved
Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65\*10\^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
Sponsors
Wuerzburg University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patient * Male or female patients with Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI) score (Sorror) ≥3 AND/or Age 50 years or older * Primary or secondary AML Month 0, Month 1, Month 2, Month 4, Month 5, Month 6 and Month 7, in Complete Remission (CR) (\<5% blasts in bone marrow (BM)) irrespective of the cytogenetic or molecular risk profile or MDS up to Refractory anemia with excess of blasts 2 (RAEB-2) (maximal 20% blasts in bone marrow) * Planned alloHSCT with Cluster of Differentiation 34+ (CD34+)-purified stem cell grafts after conditioning with fludarabine-melphalan-thio-thepa-ATG (ATG=Antithymocyte globulin) * HLA-matched stem cell donor (9-10/10, maximal 1 allel- or antigen mismatch allowed) without aberrant CD45RA (=Cluster of Differentiation) expression Additional patient inclusion criteria: Treatment phase patients at day 30 +/-5 after alloHSCT: -Stable engraftment of the allogeneic graft (granulocytes \> 0.5\*109/L) Donor * Donor must have met requirements of European Union (EU) Tissue and Cells Directive (2004/23/EC) (see below) * Healthy donor - having passed medical examination for stem cell donation * Donor must fulfill the requirements for allogeneic donor blood testing according to Richtlinie zur Herstellung und Anwendung von hämatopoetischen Stammzellzubereitungen (SC-Richtlinie (RILI) der Bundesärztekammer; 08/2014) * Donor informed consent for the additional non-mobilized apheresis * Written informed consent of the patient
Exclusion criteria
* Patient * Disease-specific treatment foreseen in the first 6 months after alloHSCT * Patients with AML M3 * Pregnant or lactating women * Severe psychological disturbances * Positive serology for Human immunodeficiency virus (HIV), Syphilis, West Nile Virus (WNV) * Participation in another interventional clinical trial during or within 4 weeks before study entry Additional patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative incidence of acute GVHD > overall grade II or death | during three months after the infusion of the T cell product | Toxicity of the infusion will be evaluated by the cumulative incidence of acute GVHD \> overall grade II or death during three months after the infusion of the T cell product. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical signs of viral infections - fever in °celsius | During 10 months after first application until study end (per patient) | Clinical signs of viral infections - fever in °celsius |
| Incidence of relapse | During 10 months after first application until study end (per patient) | — |
| Incidence of bacterial and fungal infections | During 10 months after first application until study end (per patient) | — |
| Incidence of GvHD grade II-IV | During 10 months after first application until study end (per patient) | — |
| Appearance or Expansion of antigen specific T cells measured in specific T cells per mikroliter | during 9 months after first infusion | the determination of appearance or expansion of antigen specific T cells (measured in specific T cells per mikroliter) from donor derived TCM during 36 weeks (9 months) after the first infusion of study medication. |
| Incidence of viremia and clinical manifestations of virus-related organ manifestations (Cytomegalovirus (CMV), Eppstein-Barr virus (EBV), Adenovirus, Herpes Simplex Virus (HSV), Varicella-Zoster Virus (VZV)) | During 10 months after first application until study end (per patient) | — |
| quantification of CMV specific T cells by multimer staining and ics (copies / ml) | before transfer of the first TCM dose (Month 0) and at Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8 and Month 9 after first TCM transfer. | Efficacy of the transfer of TCM will be evaluated by quantification of CMV specific T cells by multimer staining and ics before transfer of the first TCM dose (Month 0) and at Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8 and Month 9 after first TCM transfer. |
| quantification of EBV specific T cells by multimer staining and ics (copies / ml) | before transfer of the first TCM dose (Month 0) and at Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8 and Month 9 after first TCM transfer. | Efficacy of the transfer of TCM will be evaluated by quantification of EBV specific T cells by multimer staining and ics before transfer of the first TCM dose (Month 0) and at Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8 and Month 9 after first TCM transfer. |
| quantification of Adenovirus specific T cells by multimer staining and ics (copies / ml) | before transfer of the first TCM dose (Month 0) and at Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8 and Month 9 after first TCM transfer. | Efficacy of the transfer of TCM will be evaluated by quantification of Adenovirus specific T cells by multimer staining and ics before transfer of the first TCM dose (Month 0) and at Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8 and Month 9 after first TCM transfer. |
| Donor chimerism in bone marrow and peripheral blood measured in % of nucleated cells | During 10 months after first application until study end (per patient) | — |
Countries
Germany
Outcome results
None listed